Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

EOM-613 is under clinical development by EOM Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.

Cytokine release syndrome (CRS) developed in all patients, including grade 3/4 events in nearly half. "Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which ...

A recent review published in eGastroenterology discusses recent advancements in understanding alcohol-associated liver ...

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...